PHARMACEUTICAL EXPORTER IN SOUTH EAST ASIA
Actiza pharmaceuticals have been a major exporter for Southeast Asia for many years. Our elaborate export chain exists in all the major Southeast Asian countries including Indonesia, Philippines, Vietnam, Thailand, Malaysia, Singapore, Cambodia and many more. We export generic drugs, OTC products, and nutraceutical Medicines which come in various forms and dosages. We are especially known for the delivery of finished formulations that are manufactured at our own manufacturing facility. Our products are certified by reputed organizations like US FDA, GMP, WHO GMP, and ISO. After considering all the needs of our clients, we provide the best-suited export solutions at the most affordable prices. Our excellent services paired with on-time and hassle-free delivery has made us stand out. The task of Actiza Pharma does not end after the delivery itself. We try to address every follow-up query or issue from your end. This has helped us build a long-term family-like relationship with our clients. So, if you are choosing us for your export services, you can be assured to get the utmost satisfaction. Feel free to contact us if you have any further queries about our Pharmaceutical Export Service for southeast Asia
In a very short time span, we have crisscrossed the Asia Pacific, Latin America, Middle-East, Sri Lanka, Africa, CIS countries and many more.
With over 2000 products across more than 20 categories, we offer you depth and variety
We fulfill every requirement: SOPs, BSE, TSE, COO, Mol, CoA, CoPP, GSDP, FIFO
We guarantee 24hrs turnaround for all RFQs with a dedicated team for overseas trade.
Our researches and achievements have grown popular among media channels and other niche platforms.
Why choose Pharmaceutical Exports from India?
The Pharma ecosystem in India is 3rd largest in terms of volume and 13th largest in terms of value. It has evolved as a global manufacturing and research hub over the years. Today, India is the largest generic medicine supplier in the world (20 to 22% of the global export volume). The estimated compound annual growth rate (CGAR) of 22.4% will take the pharma industry in India to 55 billion US$ by the end of 2020.
The major advantage of outsourcing the pharma products from India is the cost-effectiveness while maintaining the same quality. The R & D of these Indian companies are also evolving which ensures the exports of high-quality branded medicines as well, in the near future.
With the evolving state-of-art technologies and skilled workforce, the Indian pharmaceutical industry promises a great future.